Lamisil and Skin atrophy - a phase IV clinical study of FDA data

Summary:

Skin atrophy is reported as a side effect among people who take Lamisil (terbinafine hydrochloride), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Novorapid, and have Psoriasis.

The phase IV clinical study analyzes which people have Skin atrophy when taking Lamisil. It is created by eHealthMe based on reports of 13,455 people who have side effects when taking Lamisil from the FDA, and is updated regularly.

What is Lamisil?

Lamisil has active ingredients of terbinafine hydrochloride. It is often used in pulmonary aspergilloma (mycetoma). eHealthMe is studying from 14,080 Lamisil users. Check the latest studies of Lamisil.

What is Skin atrophy?

Skin atrophy (wasting of skin) is found to be associated with 626 drugs and 714 conditions by eHealthMe. Check the latest studies of Skin atrophy.

On Jul, 04, 2026

13,455 people reported to have side effects when taking Lamisil.
Among them, 51 people (0.38%) have Skin atrophy.

Among these 51 people:

How long have people been on Lamisil when they have Skin atrophy? *

What is the gender of people who have Skin atrophy when taking Lamisil? *

female: 91.84 %
male: 8.16 %

What is the age of people who have Skin atrophy when taking Lamisil? *

What are other drugs people take besides Lamisil? *

What are other side effects people have besides Skin atrophy? *

Head Injury: 43 people, 84.31%
Stress And Anxiety: 41 people, 80.39%
Fall: 41 people, 80.39%
Headache (pain in head): 41 people, 80.39%
Poor Quality Sleep: 40 people, 78.43%
Sensory Disturbance (sense disturbance): 40 people, 78.43%
Skin Discoloration: 40 people, 78.43%
Fainting (loss of consciousness and postural tone): 40 people, 78.43%
Dyspnea (difficult or laboured breathing): 40 people, 78.43%
Renal Disorder (kidney disease): 40 people, 78.43%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 33 people, 64.71%
High Blood Pressure: 9 people, 17.65%
Nail Tinea (fungal infection of nail): 2 people, 3.92%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 1.96%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 1.96%
Nail Infection: 1 person, 1.96%
Diabetes Mellitus Inadequate Control: 1 person, 1.96%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 1.96%
Asthma: 1 person, 1.96%

* Approximation only. Some reports may have incomplete information.

Do you take Lamisil and have Skin atrophy?

- Check whether Skin atrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lamisil:

Lamisil (14,080 reports)

Skin atrophy treatments and more:

Skin atrophy (6,670 reports)

Browse all side effects of Lamisil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin atrophy:

Skin atrophy (626 drugs)

Browse all the conditions that are associated with Skin atrophy:

Skin atrophy (714 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on terbinafine hydrochloride (the active ingredients of Lamisil) and Lamisil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.